BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 10, 2001
 |  BioCentury  |  Emerging Company Profile

Integrative Proteomics: Druggability rules

A target is conventionally considered to be validated when there is evidence that modulation of a target molecule will produce a desired biological effect. Integrative Proteomics Inc. is taking that definition one step further. It hopes to churn out higher quality targets by defining a validated target as one that not only plays a role in a biological pathway, but also is one that is druggable, with a structural cleft with which a drug can interact.

"The key is the intersection of druggable targets and chemistry," according to John Mendlein, chairman and CEO. "There are a lot of targets out there, but many of them are intractable."

IPI plans to harvest opportunities in that intersection by combining its capabilities in nuclear magnetic resonance (NMR), x-ray crystallography, and mass spectroscopy (MS) with complementary...

Read the full 651 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >